20/20 BioLabs Posts Record OneTest Revenue, Eyes Broader Commercial Push
Event summary
- 20/20 BioLabs rescheduled its investor webinar to 2:00 p.m. ET on September 2, 2026, to discuss Q2 2026 results and commercial expansion.
- OneTest™ revenue hit a record $0.7 million, up 47.1% year-over-year.
- Gross margin expanded to 41.7% from 30.5%, driven by operating leverage in lab operations.
- CEO Jonathan Cohen will share insights from the Next Generation Dx Summit and state-funded firefighter screening programs.
The big picture
20/20 BioLabs is capitalizing on its strongest quarterly performance since launching its multi-cancer early detection test, leveraging record revenue and expanding gross margins to fuel broader commercial adoption. The company's focus on integrating inflammatory biomarkers with tumor markers aligns with industry trends toward preventive healthcare, while its state-funded firefighter screening programs are building real-world evidence to support regulatory and reimbursement strategies. The strategic tension lies in balancing rapid commercial expansion with the need for sustained regulatory and reimbursement momentum.
What we're watching
- Revenue Trajectory
- Whether 20/20 BioLabs can sustain its 47.1% year-over-year revenue growth in OneTest™ sales.
- Regulatory Pathway
- The pace at which the company advances its regulatory and reimbursement strategy, particularly ahead of the 2028 Medicare pathway.
- Commercial Expansion
- How effectively 20/20 BioLabs scales its commercial reach across occupational health, military, and retail channels.
Related topics